Source: China Business News Network
The repeated outbreaks of COVID-19 and the complex and ever-changing international situation have brought challenges to the recovery of the world economy and the global industrial chain and supply chain. Since March, the new round of domestic epidemics has also caused troubles and impacts on the production and operation of enterprises, including foreign companies, under multiple pressures. , what is the intention of foreign investors? Has confidence been affected? The data on China's actual use of foreign capital in the first four months again gave a positive answer, proving the charm of China's large market.
According to data released by the Ministry of Commerce, from January to April 2022, the actual use of foreign capital nationwide was 478.61 billion yuan, a year-on-year increase of 20.5% (equivalent to US$74.47 billion, a year-on-year increase of 26.1%). In terms of industry, the actual use of foreign capital in the service industry was 351.94 billion yuan, a year-on-year increase of 12.5%. The actual use of foreign capital in the high-tech industry increased by 45.6% year-on-year, of which the high-tech manufacturing industry increased by 36.7% and the high-tech service industry increased by 48.3%. From the perspective of source, the actual investment in China from South Korea, the United States and Germany increased by 76.3%, 53.2% and 80.4% respectively. In terms of regional distribution, the actual use of foreign capital in the eastern, central and western regions of China increased by 18.7%, 43.7% and 26.9% year-on-year respectively.
It is worth noting that in the first four months, there were 185 large-scale projects with new contract foreign capital of more than 100 million US dollars in China, which is equivalent to an average of 1.5 large-scale foreign-funded projects landing every day! More gratifying is that this trend continues.
On May 16, the cloud signing ceremony for foreign-funded projects in Jiangsu Province and the awarding ceremony for foreign-funded headquarters enterprises were held. At the ceremony, Suzhou Industrial Park was awarded the only provincial-level economic cluster for foreign-funded headquarters. At the same time, five major projects in Wuxi City achieved centralized signing. The total investment of this batch of projects is 740 million US dollars, involving medical equipment, high-end equipment and high-end manufacturing, biomedicine and other fields.
Among them, the Sibiman degenerative arthritis cell therapy project is a capital increase and expansion project of Sibiman Biotechnology (Wuxi) Co., Ltd. The company has received US$125 million in foreign capital since it settled in Wuxi, and plans to increase its capital by US$75 million this year to build an industrial base around related products. The person in charge of the company revealed that SIBIMAN’s stem cell drug for the treatment of degenerative arthritis is about to complete the Phase II clinical trial and can be marketed conditionally after being approved by the State Food and Drug Administration. According to the regulations, the product production base for the Phase III clinical trial of the product must be the official site for commercial production of the product. This expansion stems not only from the confidence in the product's prospects, but also from the recognition of Wuxi's development environment.
There are still many foreign companies that continue to increase their investment. A few days ago, Tai Pei Siqi Group announced the official establishment of the Group's China Travel Retail Headquarters in Hainan Free Trade Port, to further expand the travel retail business layout.
"With the continuous development and improvement of the construction of the Hainan Free Trade Port, the Hainan market continues to release strong momentum. The vigorous development momentum and the continuously optimized business environment attract and encourage us to make great strides." Yang Baoyan, President, President and CEO of Coach China, told reporters that Taipai Siqi's China Travel Retail Headquarters officially landed in Hainan, marking that the group's travel retail business in China will open a new chapter of rapid development. In the future, the Group hopes to join hands with more partners to jointly deepen the market layout, stimulate forward-moving energy centered on cooperation, and fully satisfy Chinese consumers' yearning for a more personalized and better lifestyle.
Also confident in the Chinese market is the Bayer Group, which has been rooted in China for 140 years. "For 140 years, Bayer has always been rooted in China. With its deep market accumulation and rich experience, Bayer has served local patients, consumers and growers." Steve, Chief Financial Officer of Bayer Greater China, said in an interview with reporters that Bayer has witnessed China has actively introduced policies and measures to inject vitality into the economy, help companies cope with operational challenges, and promote the process of steady national economic growth. Facts have proved that China's efforts have been fruitful, which has continued to strengthen the confidence of multinational companies in China, including Bayer.
In the face of the uncertainty brought about by the recent epidemic, Bayer has always responded positively to relevant policies and measures, paid close attention to the daily health needs of the people, and made every effort to cope with the challenges brought about by uncertainties in the supply chain, so as to contribute to the stable supply of medical health and agricultural products. .
According to reports, in the field of medicine and health, the production capacity enhancement project of the prescription drug Beijing factory announced by Bayer in 2020 is expected to be put into use by the end of this year. The investment of this project exceeds 50 million euros. After completion, the annual production capacity of the Beijing plant is expected to increase by about 40%; the implementation of innovative digital solutions will also be accelerated, which will once again reinforce its importance as one of the most advanced production bases for Bayer prescription drugs in the world status. In the field of agritech, the cornerstone of Bayer CropScience's new Chinese supply center in Hangzhou will be laid this year and production capacity will be expanded. For this purpose, Bayer has formulated a development strategy for the next 10 years. It will cooperate with Chinese partners to explore the path of digital agriculture, help Chinese farmers increase production and income, promote the sustainable and modern development of China's agriculture, and continue to make positive contributions to China's food security and rural revitalization. .
"China is one of Bayer's most important strategic markets and plays an important role in the global supply chain and innovation." Steve told reporters that in 2022, Bayer will build on the existing 6 production bases and 2 R&D centers. , will continue to take root in China, increase local investment and cooperation, seize the opportunities brought by China's expansion of opening up, and work with China to write a more exciting chapter of development.
Foreign-funded enterprises draw a new blueprint for development in opening up China
Date:2022-05-23 Hits:53
